These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29704526)

  • 1. A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.
    Hanish BJ; Hackney Price JF; Kaneko I; Ma N; van der Vaart A; Wagner CE; Jurutka PW; Marshall PA
    Steroids; 2018 Jul; 135():36-49. PubMed ID: 29704526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB).
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sabir ZL; Staniszewski LJP; Warda A; Maiorella EL; Minasian A; Davidson J; Ibrahim SJ; Raban S; Haddad D; Khamisi M; Suban SL; Dawson BJ; Candia R; Ziller JW; Lee MY; Liu C; Liu W; Marshall PA; Welch JS; Wagner CE
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
    Wagner CE; Jurutka PW
    Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
    Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
    Zhang D; Leal AS; Carapellucci S; Shahani PH; Bhogal JS; Ibrahim S; Raban S; Jurutka PW; Marshall PA; Sporn MB; Wagner CE; Liby KT
    Cancer Prev Res (Phila); 2019 Apr; 12(4):211-224. PubMed ID: 30760500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
    Jurutka PW; Wagner CE
    Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.
    Pettersson F; Hanna N; Lagodich M; Dupéré-Richer D; Couture MC; Choi C; Miller WH
    J Biol Chem; 2008 Aug; 283(32):21945-52. PubMed ID: 18544536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dataset on the response of Hut78 cells to novel rexinoids.
    Hackney Price J; Hanish BJ; Wagner CE; Kaneko I; Jurutka PW; Marshall PA
    Data Brief; 2018 Oct; 20():1797-1803. PubMed ID: 30294626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
    Inoue M; Tanabe H; Nakashima K; Ishida Y; Kotani H
    J Nat Prod; 2014 Jul; 77(7):1670-7. PubMed ID: 24959987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rexinoids Induce Differential Gene Expression in Human Glioblastoma Cells and Protein-Protein Interactions in a Yeast Two-Hybrid System.
    Hackney JF; Broatch JE; Dallal RA; Brotherson C; Livingston S; Sabir Z; Reshi SM; Faltermeier Petras SR; Mallick S; Applegate MT; Mellor NJ; Buss K; Blain JM; Wagner CE; Jurutka PW; Marshall PA
    ACS Chem Neurosci; 2024 Aug; 15(15):2897-2915. PubMed ID: 39012782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
    Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT
    Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of differential secondary effects of novel rexinoids: select rexinoid X receptor ligands demonstrate differentiated side effect profiles.
    Marshall PA; Jurutka PW; Wagner CE; van der Vaart A; Kaneko I; Chavez PI; Ma N; Bhogal JS; Shahani P; Swierski JC; MacNeill M
    Pharmacol Res Perspect; 2015 Mar; 3(2):e00122. PubMed ID: 26038698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
    Gorgun G; Foss F
    Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next-generation retinoid X receptor agonists increase ATRA signaling in organotypic epithelium cultures and have distinct effects on receptor dynamics.
    Melo N; Belyaeva OV; Berger WK; Halasz L; Yu J; Pilli N; Yang Z; Klyuyeva AV; Elmets CA; Atigadda V; Muccio DD; Kane MA; Nagy L; Kedishvili NY; Renfrow MB
    J Biol Chem; 2023 Jan; 299(1):102746. PubMed ID: 36436565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating Novel RXR Agonists That Induce ApoE and Tyrosine Hydroxylase in Cultured Human Glioblastoma Cells.
    Mallick S; Marshall PA; Wagner CE; Heck MC; Sabir ZL; Sabir MS; Dussik CM; Grozic A; Kaneko I; Jurutka PW
    ACS Chem Neurosci; 2021 Mar; 12(5):857-871. PubMed ID: 33570383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
    Rigas JR; Dragnev KH
    Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.
    Li Y; Zhang Y; Hill J; Kim HT; Shen Q; Bissonnette RP; Lamph WW; Brown PH
    Br J Cancer; 2008 Apr; 98(8):1380-8. PubMed ID: 18362934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors.
    Sanchez PV; Glantz ST; Scotland S; Kasner MT; Carroll M
    Leukemia; 2014 Apr; 28(4):749-60. PubMed ID: 23823656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling, synthesis and biological evaluation of potential retinoid X receptor (RXR) selective agonists: novel analogues of 4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethynyl]benzoic acid (bexarotene).
    Wagner CE; Jurutka PW; Marshall PA; Groy TL; van der Vaart A; Ziller JW; Furmick JK; Graeber ME; Matro E; Miguel BV; Tran IT; Kwon J; Tedeschi JN; Moosavi S; Danishyar A; Philp JS; Khamees RO; Jackson JN; Grupe DK; Badshah SL; Hart JW
    J Med Chem; 2009 Oct; 52(19):5950-66. PubMed ID: 19791803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.